Selective Ru(II)/lawsone complexes inhibiting tumor cell growth by apoptosis

Area of Science:

• Inorganic Chemistry
• Medicinal Chemistry
• Cancer Research

Background:

• Ruthenium(II) complexes are explored for their therapeutic potential.
• Lawsone derivatives offer a scaffold for novel drug development.
• Targeting cancer cell apoptosis and proliferation is a key strategy in oncology.

Purpose of the Study:

• To synthesize and characterize new trans-[Ru(law)(PPh3)2(N-N)]PF6 complexes.
• To evaluate the in vitro cytotoxicity and selectivity of these complexes against various cancer cell lines.
• To investigate the mechanism of action, including apoptosis induction, cell migration inhibition, and cell cycle arrest.

Main Methods:

• Synthesis and characterization of five Ru(II)-lawsone complexes.
• Cytotoxicity assays using DU-145, MCF-7, A549, and MRC-5 cell lines.
• Flow cytometry for apoptosis analysis and cell cycle studies.
• Circular dichroism and fluorescence quenching for DNA and human serum albumin (HSA) interaction studies.

Main Results:

• All synthesized complexes exhibited promising IC50 values, outperforming cisplatin against tested cancer cell lines.
• Complex (5) showed high selectivity and potent cytotoxic activity against A549 lung cancer cells.
• Complex (5) effectively inhibited cancer cell migration and induced apoptosis, leading to cell cycle arrest at the Sub G1 phase.
• Complexes demonstrated weak interaction with CT-DNA but strong binding with HSA via non-covalent forces.

Conclusions:

• The novel Ru(II)-lawsone complexes possess significant anticancer properties.
• Complex (5) is a promising candidate for further development as an anticancer agent, particularly for lung cancer.
• The mechanism involves apoptosis induction, migration inhibition, and cell cycle disruption, with interactions primarily with HSA rather than DNA.